Briviact 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0040 
B.IV.1.a.1 - Change of a measuring or administration 
09/01/2024 
PL 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
IB/0039/G 
This was an application for a group of variations. 
13/11/2023 
SmPC 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.b.z - Stability of FP - Extension of the shelf 
life of the finished product - Other variation 
IB/0038 
C.I.z - Changes (Safety/Efficacy) of Human and 
13/03/2023 
n/a 
Veterinary Medicinal Products - Other variation 
II/0037/G 
This was an application for a group of variations. 
09/02/2023 
SmPC and PL 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
IB/0036/G 
This was an application for a group of variations. 
22/07/2022 
n/a 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.I.b.1.d - Change in the specification parameters 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
II/0032/G 
This was an application for a group of variations. 
27/01/2022 
24/02/2022 
SmPC, 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
life of the finished product - After first opening 
(supported by real time data) 
Labelling and 
PL 
PSUSA/10447
Periodic Safety Update EU Single assessment - 
16/09/2021 
22/11/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202101 
brivaracetam 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10447/202101. 
IAIN/0035 
B.I.a.1.a - Change in the manufacturer of AS or of a 
23/09/2021 
n/a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
II/0034/G 
This was an application for a group of variations. 
24/06/2021 
n/a 
B.I.a.1.c - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer uses a substantially different 
route of synthesis or manufacturing conditions 
B.I.a.1.c - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
proposed manufacturer uses a substantially different 
route of synthesis or manufacturing conditions 
IB/0031/G 
This was an application for a group of variations. 
28/01/2021 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
PSUSA/10447
Periodic Safety Update EU Single assessment - 
17/09/2020 
25/11/2020 
SmPC 
Refer to Scientific conclusions and grounds recommending 
/202001 
brivaracetam 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10447/202001. 
IA/0030/G 
This was an application for a group of variations. 
19/11/2020 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IA/0029/G 
This was an application for a group of variations. 
29/10/2020 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
R/0025 
Renewal of the marketing authorisation. 
23/07/2020 
09/10/2020 
SmPC, Annex 
II, Labelling 
and PL 
IB/0028/G 
This was an application for a group of variations. 
11/09/2020 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0026 
B.II.b.3.z - Change in the manufacturing process of 
16/04/2020 
n/a 
the finished or intermediate product - Other variation 
IB/0024 
B.I.b.1.z - Change in the specification parameters 
09/01/2020 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IB/0023/G 
This was an application for a group of variations. 
07/01/2020 
09/10/2020 
SmPC 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
IB/0022 
B.II.d.2.d - Change in test procedure for the finished 
11/12/2019 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
IB/0021/G 
This was an application for a group of variations. 
25/09/2019 
n/a 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Other changes to a test procedure 
(including replacement or addition) 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
PSUSA/10447
Periodic Safety Update EU Single assessment - 
05/09/2019 
n/a 
PRAC Recommendation - maintenance 
/201901 
brivaracetam 
IB/0020 
B.I.a.1.z - Change in the manufacturer of AS or of a 
29/08/2019 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IAIN/0019 
B.IV.1.a.1 - Change of a measuring or administration 
10/05/2019 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
PSUSA/10447
Periodic Safety Update EU Single assessment - 
14/02/2019 
n/a 
PRAC Recommendation - maintenance 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/201807 
brivaracetam 
IB/0017 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
18/12/2018 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IA/0015/G 
This was an application for a group of variations. 
25/09/2018 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
PSUSA/10447
Periodic Safety Update EU Single assessment - 
06/09/2018 
n/a 
PRAC Recommendation - maintenance 
/201801 
brivaracetam 
II/0010/G 
This was an application for a group of variations. 
31/05/2018 
11/07/2018 
SmPC, 
Please refer to the Scientific Discussion Briviact 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extension of Indication to include adjunctive therapy 
PL 
Labelling and 
EMEA/H/C/003898/II/0010/G. 
in the treatment of partial-onset seizures with or 
without secondary generalisation in patients with 
epilepsy 4 years of age and older for Briviact. As a 
consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 
and 6.5 of the SmPC are updated. 
In addition, the Marketing authorisation holder 
(MAH) has provided a 5ml oral dosing syringe and 
adaptor for the 10mg/ml oral solution, for use in the 
paediatric population. 
B.IV.1.a.1 - Change of a measuring or administration 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
PSUSA/10447
Periodic Safety Update EU Single assessment - 
08/02/2018 
n/a 
PRAC Recommendation - maintenance 
/201707 
brivaracetam 
IAIN/0013 
A.2.a - Administrative change - Change in the 
08/01/2018 
11/07/2018 
SmPC, 
The Italian SmPC, labelling and PL have been updated to 
(invented) name of the medicinal product for CAPs 
Labelling and 
reflect the approved name for the medicinal product for the 
PL 
Italian market: Nubriveo. 
IA/0012/G 
This was an application for a group of variations. 
27/11/2017 
n/a 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
PSUSA/10447
Periodic Safety Update EU Single assessment - 
01/09/2017 
n/a 
PRAC Recommendation - maintenance 
/201701 
brivaracetam 
PSUSA/10447
Periodic Safety Update EU Single assessment - 
23/02/2017 
20/04/2017 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201607 
brivaracetam 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10447/201607. 
IB/0008/G 
This was an application for a group of variations. 
20/12/2016 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0007/G 
This was an application for a group of variations. 
05/12/2016 
22/03/2017 
SmPC, 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
storage conditions of the finished product - Other 
variation 
Labelling and 
PL 
IA/0005/G 
This was an application for a group of variations. 
01/09/2016 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
N/0004 
Minor change in labelling or package leaflet not 
21/06/2016 
22/03/2017 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
IB/0003 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
04/05/2016 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IAIN/0002/G 
This was an application for a group of variations. 
07/04/2016 
22/03/2017 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
Labelling and 
PL 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IAIN/0001 
B.II.e.5.a.1 - Change in pack size of the finished 
07/04/2016 
22/03/2017 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 12/12 
 
 
 
 
 
 
 
 
 
